These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 25614222)

  • 1. Applying thermodynamic profiling in lead finding and optimization.
    Klebe G
    Nat Rev Drug Discov; 2015 Feb; 14(2):95-110. PubMed ID: 25614222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery.
    Williams G; Ferenczy GG; Ulander J; Keserű GM
    Drug Discov Today; 2017 Apr; 22(4):681-689. PubMed ID: 27916639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.
    Lu H; Iuliano JN; Tonge PJ
    Curr Opin Chem Biol; 2018 Jun; 44():101-109. PubMed ID: 29986213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of ligand efficiency metrics in drug discovery.
    Hopkins AL; Keserü GM; Leeson PD; Rees DC; Reynolds CH
    Nat Rev Drug Discov; 2014 Feb; 13(2):105-21. PubMed ID: 24481311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermodynamic profiling for fragment-based lead discovery and optimization.
    Ferenczy GG; Keserű GM
    Expert Opin Drug Discov; 2020 Jan; 15(1):117-129. PubMed ID: 31741402
    [No Abstract]   [Full Text] [Related]  

  • 6. New approaches for computing ligand-receptor binding kinetics.
    Bruce NJ; Ganotra GK; Kokh DB; Sadiq SK; Wade RC
    Curr Opin Struct Biol; 2018 Apr; 49():1-10. PubMed ID: 29132080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native Mass Spectrometry in Fragment-Based Drug Discovery.
    Pedro L; Quinn RJ
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular fields in ligand discovery.
    Gane PJ; Chan AW
    Methods Mol Biol; 2013; 1008():479-99. PubMed ID: 23729264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Critical Review of Validation, Blind Testing, and Real- World Use of Alchemical Protein-Ligand Binding Free Energy Calculations.
    Abel R; Wang L; Mobley DL; Friesner RA
    Curr Top Med Chem; 2017; 17(23):2577-2585. PubMed ID: 28413950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermodynamics of fragment binding.
    Ferenczy GG; Keserű GM
    J Chem Inf Model; 2012 Apr; 52(4):1039-45. PubMed ID: 22458364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.
    Ferreira LG; Andricopulo AD
    Curr Top Med Chem; 2017; 17(20):2260-2270. PubMed ID: 28240184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of binding thermodynamics on medicinal chemistry optimizations.
    Ferenczy GG; Keserű GM
    Future Med Chem; 2015; 7(10):1285-303. PubMed ID: 26144265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From fragment screening to potent binders: strategies for fragment-to-lead evolution.
    Eitner K; Koch U
    Mini Rev Med Chem; 2009 Jul; 9(8):956-61. PubMed ID: 19601891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based virtual screening for novel ligands.
    Pitt WR; Calmiano MD; Kroeplien B; Taylor RD; Turner JP; King MA
    Methods Mol Biol; 2013; 1008():501-19. PubMed ID: 23729265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of small-molecule structures to complement protein-ligand crystal structures in drug discovery.
    Groom CR; Cole JC
    Acta Crystallogr D Struct Biol; 2017 Mar; 73(Pt 3):240-245. PubMed ID: 28291759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ligand efficiency and lead optimization].
    Guo ZR
    Yao Xue Xue Bao; 2013 Dec; 48(12):1755-62. PubMed ID: 24689231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the future for fragment-based drug discovery?
    Keserű GM; Hann MM
    Future Med Chem; 2017 Sep; 9(13):1457-1460. PubMed ID: 28795595
    [No Abstract]   [Full Text] [Related]  

  • 20. How well can fragments explore accessed chemical space? A case study from heat shock protein 90.
    Roughley SD; Hubbard RE
    J Med Chem; 2011 Jun; 54(12):3989-4005. PubMed ID: 21561141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.